FDA Inspection 611945 — Celgene Corporation

Celgene Corporation — FEI 3004991673

The FDA completed an inspection of Celgene Corporation on Sep 3, 2009 in Summit, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 6 citations were issued during this inspection. Product area: Drugs.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Sep 3, 2009
Fiscal Year
2009
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Summit, NJ (United States)

Additional details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
672821 CFR 314.80(b)Failure to review ADE information
673021 CFR 314.80(b)Failure to develop written procedures
673221 CFR 314.80(c)(1)(i)Late submission of 15-day report
673721 CFR 314.80(c)(1)(ii)Failure to separately submit original and follow-up reports
682921 CFR 314.80(c)(2)Failure to report non-alert ADEs
683121 CFR 314.80(c)(2)Late submission of quarterly safety reports

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.